Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mircera maintenance treatment for anemia in CKD patients on dialysis
NCT00077610Phase 3Completed
- Sponsor
- Roche
- Start
- Feb 2004
- Primary completion
- Aug 2005
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of methoxy polyethylene glycol-epoetin beta in anemia of chronic kidney disease (CKD-A) (3 arms), sponsored by Roche. Primary endpoint: Mean Change in Hemoglobin Concentration From Baseline to Evaluation Period at Week 36. Started Feb 2004; status: completed.
02
Drugs
methoxy polyethylene glycol-epoetin beta
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT00077610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00077610.